-
Sector Analysis
Epilepsy: Epidemiology Report and Forecast to 2035
Epilepsy is a neurological condition defined by repeated, unpredictable seizures resulting from abrupt, chaotic, and intense electrical activity among brain cells (World Health Organization, 2024a). Globally, it ranks as one of the most widespread neurological disorders (World Health Organization, 2024a). This chronic condition can develop at any point in a person's life. A diagnosis typically occurs after an individual experiences at least one seizure and sees a specialist, who evaluates detailed accounts of both the pre-seizure warning signs and the...
-
Product Insights
Alzheimer's Disease: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Alzheimer's Disease - Global Clinical Trials Review, 2026" provides an overview of Alzheimer's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Amyotrophic Lateral Sclerosis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2026" provides an overview of Amyotrophic Lateral Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Cerebral Palsy: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Cerebral Palsy - Global Clinical Trials Review, 2026" provides an overview of Cerebral Palsy Clinical trials scenario. This report provides top line data relating to the clinical trials on Cerebral Palsy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2026" provides an overview of Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Clinical trials scenario. This report provides top line data relating to the clinical trials on Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Product Insights
Parkinson's Disease - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Parkinson's Disease - Global Clinical Trials Review, 2026" provides an overview of Parkinson's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Parkinson's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Huntington Disease - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Huntington Disease - Global Clinical Trials Review, 2026" provides an overview of Huntington Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Huntington Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Encephalitis - Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Encephalitis - Global Clinical Trials Review, 2025" provides an overview of Encephalitis Clinical trials scenario. This report provides top line data relating to the clinical trials on Encephalitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032
Understand the Future of the Insomnia Therapeutics Market The insomnia therapeutics market continues to evolve as treatment innovation, unmet patient needs, and changing prescribing patterns reshape the competitive landscape. This report provides a comprehensive analysis of the insomnia market across the 7MM, supported by an Excel-based forecast model covering the period from 2022 to 2032. Z-drugs remain the most common first-line treatment across the US and 5EU markets, while the current pipeline remains limited but diverse, featuring products with varying...
-
Sector Analysis
Huntington’s Disease Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Huntington’s Disease market through 2034. The current HD treatments are used to alleviate the symptoms associated with the disease, with all of the approved drugs indicated for the management of chorea associated with HD. VMAT2 inhibitors dominated the HD market in 2024, accounting for 99.8% of sales in the 7MM. The key focus in the pipeline is on developing DMTs for HD, and huntingtin-lowering strategies are key...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.